ERBITUX for Squamous cell carcinoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 12 adverse event reports in the FDA FAERS database where ERBITUX was used for Squamous cell carcinoma.
Most Reported Side Effects for ERBITUX
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Rash | 114 | 17.1% | 1 | 3 |
| Infusion related reaction | 44 | 6.6% | 1 | 6 |
| Malaise | 37 | 5.6% | 0 | 1 |
| Speech disorder | 32 | 4.8% | 1 | 0 |
| Dry skin | 31 | 4.7% | 0 | 0 |
| Diarrhoea | 25 | 3.8% | 1 | 6 |
| Pruritus | 24 | 3.6% | 0 | 2 |
| Death | 23 | 3.5% | 23 | 4 |
| Adverse event | 21 | 3.2% | 1 | 9 |
| Malignant neoplasm progression | 20 | 3.0% | 10 | 4 |
| Dyspnoea | 19 | 2.9% | 1 | 6 |
| Acne | 18 | 2.7% | 1 | 1 |
| Hypomagnesaemia | 18 | 2.7% | 0 | 1 |
| Skin disorder | 18 | 2.7% | 0 | 0 |
| Weight decreased | 18 | 2.7% | 2 | 3 |
Other Indications for ERBITUX
Head and neck cancer (70)
Colon cancer (56)
Colorectal cancer (39)
Colorectal cancer metastatic (28)
Colon cancer metastatic (17)
Throat cancer (12)
Neoplasm malignant (7)
Rectal cancer (7)
Lung neoplasm malignant (6)
Product used for unknown indication (6)
Other Drugs Used for Squamous cell carcinoma
CARBOPLATIN (608)
CISPLATIN (522)
PACLITAXEL (496)
PEMBROLIZUMAB (470)
FLUOROURACIL (430)
NIVOLUMAB (343)
CETUXIMAB (283)
CEMIPLIMAB-RWLC (234)
DOCETAXEL (198)
GEMCITABINE (109)